remove_red_eye 676 Views
#Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine
Assessment of patient blood eosinophil count and smoking status may help optimize treatment with inhaled corticosteroids (ICS), a post-hoc analysis of the pivotal IMPACT trial noted.
Prospective modeling of blood eosinophil count as a continuous measure, rather than a single cut-off eosinophil threshold, showed greater response to ICS in terms of exacerbation reduction with increasingly greater blood eosinophil count in patients with moderate-to-severe COPD with at least one exacerbation over the previous year, reported Steven Pascoe, MBBS, and colleagues.
Patient smoking status interacted with eosinophil count to predict ICS response, with former smokers more likely to benefit from treatment with ICS than current smokers, reported the authors in the Lancet Respiratory Medicine.